Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters
The collaboration between CORONA and Ferring will cater to patients across India
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
New agreement applies to the polymers of the Medical Care series portfolio
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Subscribe To Our Newsletter & Stay Updated